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Abstract
HMGA1 is a member of a small family of architectural transcription factors involved in the coordinate assembly of
multiprotein complexes referred to as enhanceosomes. In addition to their role in cell proliferation, differentiation,
and development, high-mobility group proteins of the A type (HMGA) family members behave as transforming pro-
toncogenes either in vitro or in animal models. Recent reports indicated that HMGA1 might counteract p53 pathway
and provided an interesting hint on the mechanisms determining HMGA’s transforming potential. HMGA1 expres-
sion is deregulated in a very large array of human tumors, including cervical cancer, but very limited information is
available on the molecular mechanisms leading to HMGA1 deregulation in cancer cells. Here, we report that HMGA1
expression is sustained by human papilloma virus (HPV) E6/E7 proteins in cervical cancer, as demonstrated by either
E6/E7 overexpression or by repression through RNA interference. Knocking down HMGA1 expression by means of
RNA interference, we also showed that it is involved in cell proliferation and contributes to p53 inactivation in this
type of neoplasia. Finally, we show that HMGA1 is necessary for the full expression of HPV18 E6 and E7 oncopro-
teins thus establishing a positive autoregulatory loop between HPV E6/E7 and HMGA1 expression.
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Introduction
High-mobility group proteins of the A type (HMGA) are a small
family of nonhistonic architectural transcription factors, comprising
at least three major members: HMGA1a, HMGA1b, and HMGA2
[1]. Their ability to bind the minor groove of DNA and to interact
with a large number of proteins allow them to coordinate the assem-
bly and disassembly of multiprotein transcription complexes called
enhanceosomes and to control transcription of an ample number of
genes [1–5]. HMGA family members are strongly expressed in early
developmental stages, where they are involved in controlling cell pro-
liferation and differentiation. Indeed, inactivation of HMGA2 leads
to the mouse “pigmy” phenotype [6], whereas overexpression of an
active HMGA2 confers a giant phenotype in transgenic animals [7].
HMGA expression declines to very low levels in most adult differen-
tiated tissues, but it is deregulated in human tumors of both mesen-
chymal and epithelial origin. HMGA1, in particular, is overexpressed
in carcinomas of the thyroid [8], colon [9–11], prostate [12,13], pan-
creas [14], ovary [15], and breast [16] and in neuroblastoma [17]. Its
increased expression may be associated to more aggressive and/or
metastatic stages [12,16,18,19]. HMGA proteins possess transform-
ing activity, both in vitro and in animal models [20–26]. This might
be related to their role in gene transcription [1] but might also in-
volve the inhibition of oncosuppressive pathways. Indeed, HMGA1
binds and counteracts p53 [27,28]. Furthermore, it binds and, if in
molar excess, delocalizes to the cytoplasm HIPK2 [29], one of the
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kinases responsible for p53 serine 46 phosphorylation committing p53
toward an apoptotic response [30]. Relatively little is known on the
mechanisms leading to HMGA deregulation in human tumors. On-
cogenic pathways, such as those sustained by MYCN, c-myc and ras
might be relevant in specific neoplasia [22,31,32].
Cervical cancer is the second most common cancer in women. Its
epidemiology is strongly linked to human papilloma virus (HPV) infec-
tion that is necessary, but not sufficient, for the development of virtu-
ally all cervical squamous cell carcinomas and for approximately 95% of
the adenocarcinomas. Human papilloma virus infection is a very com-
mon phenomenon, but in 80% of the cases, the infection is quickly
cleared. Persistence of the infection of the “high-risk” strains (HPV16
and 18) is frequently associated to the development of noninvasive squa-
mous precursor lesions called cervical intraepithelial neoplasia (CIN) [33–
35]. Cervical intraepithelial neoplasia might vary from CIN-1 to CIN-3,
mostly depending on the grading of dysplasia. E6 and E7 HPV proteins
are necessary for the induction and maintenance of the transformed phe-
notype, mostly through the inactivation of p53 (through E6-mediated
degradation) and RB (by means of E7 binding) pathways [36,37].
The Notch pathway is an important tuner of cell proliferation and
differentiation whose deregulation contributes to human carcinogen-
esis. In cervical cancer, conflicting reports described either Notch1
increased expression and functional cooperation with HPV oncopro-
teins [38–41] or the requirement for Notch1 signaling downmodu-
lation to maintain the transformed phenotype and HPV E6/E7
expression [42,43]. The levels of Notch1 overexpression achieved
in the different experimental settings might be at least partially re-
sponsible for these contrasting evidences [44]. Nevertheless, Notch1
is an oncosuppressor in the epithelial context, in vivo [45]. In addi-
tion, because p53 might directly induce Notch1 expression [46–48],
its repression by HPV oncoproteins might be responsible for the im-
pairment of Notch1 oncosuppression in cervical carcinogenesis [47].
HMGA1 expression in cervical cancer has been previously reported
[49], but the mechanism and the consequences of this have not been
addressed. By using Notch1 as a tool to convey growth inhibitory sig-
nals, we show that HMGA1 expression in cervical cancer cells is sus-
tained by HPV E6/E7 proteins. We also show that HMGA1 repression
through RNA interference inhibits cell proliferation and contributes to
p53 reactivation leading to sensitization to DNA-damaging drugs in
cooperation with Notch1. Finally, we show that HMGA1 is necessary
for the full expression of HPV18 E6 and E7 oncoproteins, thus estab-




Human cervical cancer cells (HeLa, SiHa, and Caski) cells were
maintained in standard conditions in Dulbecco’s modified Eagle’s
medium. HeLa E6/E7 cells (expressing the HPV16 E6/E7 transcript
under the control of an heterologous promoter) were kindly provided
by Dr. D. DiMaio and grown as indicated [50]. Recombinant ade-
noviruses expressing the constitutively active form of human Notch1
and the green fluorescent protein (GFP) were previously described
[43]. Viruses were used at a multiplicity of infection of 100.
Plasmids, Transfections, and Luciferase Assay
The expression plasmids for activated Notch1 and the HPV18
promoter luciferase reporter construct (pGL3–HPV18LCR) were
previously described [43]. Transient transfections were achieved by
means of the Lipofectamine 2000 Reagent (Invitrogen, San Diego,
CA) according to the manufacturer’s instructions. PG13 p53 lucifer-
ase reporter construct was stabilized in HeLa cells by a short cycle of
puromicin selection. Luciferase reporter construct assays were per-
formed using a Luciferase Reporter Assay System (Promega Corpo-
ration, Madison, WI). Cells were lysed, and luciferase activity was
determined using a Veritas automatic dual-injector luminometer
(Turner Biosystems, Sunnyvale, CA). Data were normalized on a Re-
nilla luciferase reporter construct and/or on protein content. All con-
ditions were tested in duplicate samples, and experiments were
repeated at least three times.
RNA Preparation and Real-Time Quantitative Polymerase
Chain Reaction Analysis
Total RNAwas extracted using the RNeasy system (Qiagen, Hilden,
Germany) or the TRIzol reagent (Invitrogen). For quantitative reverse
transcription–polymerase chain reaction (RT-PCR) analysis, total
RNA (1 μg) was reverse-transcribed using GeneAmp-Gold RNA
PCR Core Kit (Applied Biosystems, Warrington, United Kingdom).
One-twentieth of this reaction was employed for real-time quantitative
PCR using either SYBR Green or TaqMan PCR Master Mixes (Ap-
plied Biosystems). The analysis of human HMGA1, HES1, p21, β-actin
mRNA, and that of HPV16 and 18 E6/E7 transcripts was performed
with designed (HMGA1, E6/E7) and commercial ABI reagents using
the ABI Prism 7900HT Sequence Detection System (Applied Biosys-
tems). All amplification reactions were done in triplicate, and the
averages of the threshold cycles were used to interpolate standard
curves and to calculate transcript amounts using SDS version 1.7a
software (Applied Biosystems). Results were normalized on endoge-
nous controls, glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and β-actin.
Western Blot
Protein extracts were made in Laemmli buffer and were separated
on SDS-PAGE, blotted onto nitrocellulose membrane (Schleicher &
Schuell, Dassel, Germany), blocked in 10% nonfat dry milk, and
probed with various antibodies [goat anti-Notch1 (C-20), rabbit anti-
p21, mouse anti-p53, goat anti–β-actin, rabbit anti–ERK1/2, and
mouse anti–phospho-ERK1/2 (Santa Cruz Biotechnology, Santa Cruz,
CA); rabbit anti-CREB (kindly provided by Luca Canettieri); and
rabbit anti-HMGA1 (kindly provided by Dr. G. Manfioletti)]. HRP-
conjugated secondary antibodies were from Santa Cruz Biotechnology.
Immunoreactive bands were visualized by enhanced chemilumines-
cence (Pierce Chemical Co., Rockford, IL).
RNA Interference and Cell Proliferation Assays
RNA interference on HPV16 E6/E7 transcript was achieved by
means of the small interfering RNA (siRNA) duplex HPV16 E7
(sense seq: GCATGGAGATACTCCTACA) previously described
[51], synthesized by Dharmacon Res., Inc. (Lafayatte, CO), and
transfected in SiHa cells with Dharmafect 1 according to the manu-
facturer’s instructions. RNA interference on HMGA1 was achieved
by means of siRNA duplexes si-A1-pool or si-A1–4 (a pool of four
different siRNA against HMGA1, respectively, with one of them used
singly, produced by Dharmacon Res., Inc.) or PLKO vectors expressing
shRNA (Sigma-Aldrich Co., St. Louis, MO). HeLa cells were plated
in multiwell 24 plates and were transfected either with (5 nM) A1-
pool or A1–4 or nonspecific siRNA (NT) siRNA duplexes, or vehicle
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only, by using the Hiperfect reagent (Qiagen), according to the man-
ufacturer’s instructions. Three days after plating, cells were detached by
trypsinization and split in six replicate wells or plated in chamber slides
for 5′-bromo-2′-deoxyuridine (BrdU) labeling assay. The following
day, cells were retransfected as previously mentioned. At day 6 after
initial plating, cells were processed for RNA and protein extraction.
For BrdU incorporation assay, at day 6 from initial plating and after
11 hours of pulse with BrdU, cells were processed by means of a BrdU
labeling and detection kit (Roche Diagnostics, Indianapolis, IN).
For long-term colony growth assays, 2 × 106 HeLa cells were trans-
fected with 8 μg of either PLKO A1–49, A1–51, or A1–53 plasmids
(targeting different regions of HMGA1 transcript) or with the no-
target NT PLKO construct. After a short (3 days) cycle of puromicin
selection, cells were monitored for HMGA1 mRNA expression or re-
plated in duplicates for colony formation assay. After 2 weeks, colonies
were stained with Coomassie solution (50% methanol, 10% acetic
acid, 0.05% Coomassie blue R-250 powder) and were scored.
Results
HPV E6/E7 Oncoproteins Sustain HMGA1 Expression in
Human Cervical Cancer Cells
Invasive uterine cervical carcinomas are characterized by high
HMGA1 expression, a condition reproduced by a number of cervical
cancer cell lines, in vitro [49]. However, the mechanisms through
which HMGA1 expression is deregulated in these tumors have not
been fully elucidated. Therefore, we sought to study whether growth
inhibitory and oncosuppressive stimuli, such as those conveyed by
Notch1 signaling, could affect HMGA1 expression in these settings.
Adenoviral delivery of the activated form of Notch1 (Ad-N1ICD)
clearly repressed HMGA1 protein expression in HeLa cells (Figure 1A)
but failed to do so in Caski and SiHa cells (Figure 1A). As previously
reported [42], Notch1 activated the ERK pathway and increased Hes1
expression in the three cell lines (not shown). At the mRNA level,
again Notch1 repressed HMGA1 expression in HeLa but not in SiHa
cells (Figure 1B). This result is reminiscent of Notch1’s ability to effi-
ciently repress E6/E7 expression in HeLa but not in SiHa and Caski
cells, as we previously observed (Figure 1B and Talora et al. [42]). To-
gether with the observation of a slower kinetics of HMGA1 repression
compared to E6/E7 transcript repression on Ad-N1ICD infection (not
shown), these data suggest an association between the effects of
Notch1 on E6/E7 and the levels of HMGA1 expression. To directly
test the contribution of HPV oncoproteins to maintaining HMGA1
expression in human cervical cancer cell lines, we used HeLa E6–E7
cells, where the HPV16 E6/E7 transcript is controlled by a heterolo-
gous promoter [50]. In these cells, Ad-N1ICD infection resulted in the
repression of the endogenous HPV18 E6/E7 transcript (not shown)
but left the expression of the exogenous HPV16 E6/E7 transcript al-
most unaffected (Figure 1B). Under these conditions, repression of
HMGA1 mRNAwas far more modest compared to control HeLa cells
and did not result in any significant protein change (Figure 1, A and B)
suggesting that HPV E6/E7 oncoproteins might be directly involved
in stimulating HMGA1 expression. To confirm the role of HPV on-
coproteins in sustaining HMGA1 expression in cervical cancer, we
knocked down E6/E7 transcript in the SiHa cell line by means of
Figure 1. Notch1 represses HMGA1 expression in HeLa cervical cancer cells via HPV E6/E7 downmodulation. (A) Total proteins ex-
tracted from cells infected with an adenovirus expressing Notch1 constitutively active intracellular domain (Ad-N1ICD) or a control ad-
enovirus (Ad-GFP) were analyzed for HMGA1 expression. (B) Total RNA extracted from cells infected with Ad-GFP (black bars) or Ad-
N1ICD (white bars) were analyzed for the expression of HMGA1 and HPV E6/E7 transcripts (HPV18 E6/E7 for HeLa cells and HPV16 E6/E7
for SiHa and HeLa E6–E7 cells) by quantitative PCR. (C) SiHa cells transfected with the si-NT (black bars) or the si-E7 (white bars) de-
scribed in the Materials and Methods section were analyzed by quantitative PCR for the expression of HMGA1 and HPV16 E6/E7 tran-
scripts. For (B and C), results were normalized on GAPDH mRNA levels, and expressed as percentage relative to the control samples.
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an interfering RNA known to inhibit both E6 and E7 expression [51].
Consistent with the hypothesis, E6/E7 repression resulted in approx-
imately 55% reduction of HMGA1 expression also in SiHa cells
(Figure 1C). Overall, these results indicate that HMGA1 expression
is directly sustained by HPV E6 and/or E7 protein expression in cer-
vical cancer cells.
HMGA1 Knock Down Impairs Cervical Cancer Cell
Proliferation and Cooperates with Notch1 to Increase p53
Activity and to Sensitize Cells to Cisplatinum
HMGA1 has been described as a potential oncogene whose expres-
sion is inappropriately increased in several cancer types. To test whether
and how it could contribute to cervical carcinogenesis, we investigated
on the consequences of HMGA1 depletion in HeLa cells, by means of
short hairpin (sh-) or small interfering (si-) RNA. Transfection of three
distinct sh-vectors against human HMGA1 leads to reduced colony-
forming capability in HeLa cells (Figure 2, A and B), with an efficiency
proportional to their effect on the HMGA1 transcript expression
(Figure 2C ). These results were consistent with a reduction in the
BrdU incorporation observed in HeLa cells transiently transfected with
siRNA against HMGA1, which efficiently reduced HMGA1 transcript
(not shown) and protein expression (Figure 2, D and E).
In cervical cancer cells, activation of Notch1 signaling has been as-
sociated to cell growth inhibition dependent on E47 degradation and/
or on p53 accumulation [42]. The latter condition specifically occurs
in HeLa cells on E6 repression due to a Notch1-dependent inhibition
of the AP1 transcriptional activity on the E6/E7 promoter [43].
HMGA1 was recently reported to counteract p53-oncosuppressive
activities [27–29]. Because p53 inactivation by HPV is a funda-
mental step in cervical carcinogenesis, we hypothesized that the
HPV-dependent HMGA1 expression might contribute to a stronger
inactivation of p53 in cervical cancer. To test this hypothesis, we used
again Ad-N1ICD–infected HeLa cells, where the reduced expression
of the HPV18 E6 protein resulted in p53 accumulation (Figure 3A
and Talora et al. [43]) and a five-fold increase in the luciferase activity
of the PG13 p53 reporter construct (Figure 3B). Knocking down
HMGA1 expression through siRNA also resulted in an increase in
the PG13 reporter activity (Figure 3C ) and potentiated the effects
of Ad-N1ICD infection (Figure 3D). The expression of an endoge-
nous p53 target gene, such as p21, also increased by either Ad-N1ICD
Figure 2. HMGA1 knock down impairs cell growth in HeLa cervical cancer cells. (A) The colony-forming ability of HeLa cells is reduced
by transfection of three different PLKO sh-expressing vectors against HMGA1. (B) Graphical representation of the results in (A). (C)
Effects of the three different PLKO vectors on HMGA1 expression as measured by quantitative PCR. (D) DNA synthesis of HeLa cells
measured by BrdU incorporation is inhibited by cell transfection with two si-RNA oligonucleotides against HMGA1. (E) Effects of the two
si-RNA oligonucleotides on HMGA1 protein expression.
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infection or HMGA1 RNA interference, and the two conditions re-
sulted in a synergic effect (Figure 3E). These results collectively indi-
cate that Notch1 infection and HMGA1 depletion cooperate in raising
p53 activity. Increased p53 activity is expected to result in increased
cell death especially on treatment with therapeutic DNA-damaging
drugs, such as cisplatinum (CDDP). Indeed, transfection of a plasmid
vector expressing N1ICD in HeLa cells increased the rate of cell death
compared with control-transfected cells (Figure 4). In addition, it sen-
sitized HeLa cells to the effect of CDDP, raising to more than 60% the
rate of dead cells on 20-μM CDDP treatment. Interestingly, HMGA1
knock down also sensitized cells to the effect of CDDP at the highest
concentration and cooperated with Notch1 to further increase cell
death in response to the two drug concentrations (Figure 4).
HMGA1 Knock Down Impairs HPV18 E6/E7 Expression
An additional aspect of cervical carcinogenesis deals with the ob-
servation that HPV18 enhanceosome contains partially overlapping
AP1 and HMGA1 binding sites, both of which were shown to be
important for HPV18 transcriptional activity [52,53]. This impli-
cates that HMGA1 increased expression might also be relevant for
the overt E6/E7 expression at least in HPV18-infected cells. To test
this hypothesis, we looked at the effect of HMGA1 knock down on
the transcription of the pGL3–HPV18LCR reporter construct. In-
deed, we observed a very strong decrease in luciferase activity on
HMGA1 RNA interference compared to control HeLa cells (Fig-
ure 5A). Consistent with these data, we could also reproducibly de-
tect a 40% reduction in the HPV18 E6/E7 endogenous transcript
(Figure 5B), confirming the relevant role of sustained HMGA1 ex-
pression for HPV genome expression.
Discussion
Despite the largely confirmed association between HMGA1 dereg-
ulation and cancer, much less is known about the molecular events
Figure 3. Notch1 and HMGA1 knock down independently and cooperatively downmodulate p53 activity. (A) Total proteins extracted
from cells infected with Ad-N1ICD or Ad-GFP were analyzed for p53 and p21 expression. (B) HeLa cells transfected with the PG13
p53 reporter construct were then infected for 24 hours with either Ad-N1ICD or Ad-GFP and analyzed for luciferase activity. (C) HeLa
cells transfected with the PG13 p53 reporter construct were transfected with the si-A1-pool or the si-NT as described in the Materials
and Methods section and analyzed for luciferase activity. (D) HeLa cells transfected with the PG13 p53 reporter construct were trans-
fected with the si-A1-pool or the si-NT as described in the Materials and Methods section and then infected for 24 hours with either Ad-
N1ICD or Ad-GFP and analyzed for luciferase activity. (E) Quantitative PCR analysis of the expression of the endogenous p21 transcript in
HeLa cells transfected with si-NT (black bars) or si-A1-pool (white bars) infected by either Ad-N1ICD or Ad-GFP.
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leading to this phenomenon. c-myc and MYCN can increase HMGA1
expression through a direct transcriptional regulation in Burkitt lym-
phoma and neuroblastoma, respectively [22,32]. Ras pathway might
also be involved in HMGA1 deregulation in certain neoplasia [31].
Here, we investigated on the molecular mechanisms of HMGA1 de-
regulation in cervical cancer and showed that HMGA1 expression is
sustained by HPV E6 and/or E7 proteins. Indeed, by using Notch1
as a mean to convey growth inhibitory and oncosuppressive stimuli
we observed that HMGA1 down-regulation occurs only in HeLa
cells, where E6/E7 repression also occurs because of a reduced AP1
transcriptional activity [43]. Notch1-dependent HMGA1 decrease is
prevented by the overexpression of the HPV16 E6 and E7 proteins
in HeLa cells. Conversely, E6/E7 knockdown through RNAi impairs
HMGA1 expression in SiHa cells. Together with the observation that
HPV16 E6 protein induced HMGA1 expression in murine fibro-
blasts [54], our data clearly establish a link between HPV E6/E7 pro-
teins and HMGA1-deregulated expression in cervical cancer. Although
this regulation is likely to occur at the transcriptional level, we were
unable to show any effect of Notch1 in repressing the activity of the
HMGA1 promoter reporter construct we recently described [32] (not
shown). Further efforts will be necessary to better characterize the mo-
lecular details of this regulation.
HMGA1 clearly possess transforming capabilities both in vitro and
in animal models, and this might be related to its ability to modify
gene expression [20–26] and to counteract p53. Indeed, HMGA1
can bind p53 and impair its transcriptional activity either directly
[27,28] or through the cytoplasmic delocalization and inhibition of
HipK2 [29], one of the kinases phosphorylating p53 on serine 46
and turning on its proapoptotic potential [30]. In this article, we also
addressed the issue of HMGA1 contribution to cervical carcinogen-
esis. Our data clearly show that interfering with HMGA1 expression
cause reduced BrdU incorporation and impaired colony-forming
ability in HeLa cells, confirming the involvement of HMGA1 in cell
proliferation in these settings. In addition, we observed that HMGA1
interference was sufficient to induce p53 activity measured either
through a p53 luciferase reporter construct or through endogenous
p21 induction. In HPV-infected cervical cancer cells, p53 is largely
inactivated due to its binding to the E6 protein that targets it for deg-
radation. Notch1 represses E6/E7 expression in AP-1–competent cells,
such as HeLa cells, thus leading to p53 accumulation [43]. Indeed,
we could measure increased p53 activity both in the p53 luciferase
reporter assay and in terms of p21 expression. Notch1 effects could
Figure 4. Notch1 and HMGA1 knock down independently and co-
operatively sensitize HeLa cells to cisplatinum. HeLa cells were
transfected with the si-A1-pool as described in the Materials and
Methods section and then transfected with either N1ICD (black
bars) or pCDNA3 control vector (white bars), before being treated
with the indicated concentrations of cisplatinum. After 48 hours,
cells were harvested and counted in a hemocytometer.
Figure 5. HMGA1 knock down impairs HPV E6/E7 transcription. (A) HeLa cells transfected with the si-A1-pool and the si-NT as described
in the Materials and Methods section were then retransfected with the PGL3 vector (black bars) or the pGL3-HPV18LCR reporter con-
struct (white bars) and analyzed for luciferase activity. (B) HeLa cells transfected with the si-A1-pool and the si-NT as described in the
Materials and Methods section were then analyzed by quantitative PCR for the expression of HMGA1 (black bars) or HPV18 E6/E7 (white
bars) transcripts normalized on GAPDH.
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be potentiated by HMGA1 knock down, in keeping with its role in
repressing p53 activity. Furthermore, we observed that Notch1 ex-
pression could sensitize HeLa cervical cancer cells to DNA-damaging
agents such as cisplatinum. Again, HMGA1 knockdown also dis-
played a similar consequence and further exacerbated Notch1 effects.
Therefore, our data support the hypothesis that HMGA1 can contrib-
ute to cervical carcinogenesis also through its ability to impair p53
function, in addition to its ability to directly influence gene expression.
An additional aspect addressed in our article deals with the regu-
lation of HPV E6/E7 expression. During the initial phase of the in-
fection by the high-risk HPV strains (such as HPV16 and 18), E6
and E7 expression in cervical cells remains relatively low and reaches
higher levels only in differentiated squamous epithelial cells commit-
ted to shedding [55]. In contrast, E6/E7 expression reaches very high
levels in dysplastic proliferating cells of CIN-3 lesions [56,57], sug-
gesting that some kind of genetic or epigenetic switch occurred. The
precise mechanism governing the expression switch is far from being
clear. Intriguingly, HMGA1 has been reported to be essential for the
formation of an enhanceosome driving the expression of HPV18 E6/
E7 transcript [52,53]. In keeping with this, HMGA1 knockdown
inhibited HPV18 E6/E7 promoter activity in luciferase reporter assay
and reduced E6/E7 expression in HeLa cells. These results point to
the existence of a positive feedback loop between E6/E7 and HMGA1
expression. It is worth mentioning that higher HMGA1 levels are
detectable in proliferating dysplastic cervical cells of higher-grade
(CIN-3) lesions, where the E6/E7 expression switch has occurred,
rather than in infected differentiated cells [49]. Whether this loop
contributes to the previously mentioned E6/E7 expression switch
needs to be specifically addressed.
Recent literature has depicted a complex interplay between Notch1
and p53, each of which may apparently work upstream of the other
depending on the cell/tissue context [46–48]. On the basis of obser-
vation specifically made on keratinocytes, however, we can put forward
the following model (Figure 6). p53 directly controls Notch1 expres-
sion in both normal and neoplastic keratinocytes, thus contributing to
the inhibition of cell growth and induction of cell differentiation [47].
In infected keratinocytes, HPV oncoproteins reduce p53 expression
and, by inducing HMGA1, further decrease its activity leading to
Notch1 repression, inhibition of cell differentiation, and ablation of
growth inhibitory signals, thus providing a strong contribution to
carcinogenesis. Overexpression of Notch1 intracellular domain in
this context restores the original circuit. It represses E6/E7 expression
through AP-1 downmodulation [43]. As a consequence, HMGA1
expression declines, and both conditions favor the accumulation of
active p53, which in turn activates a strong oncosuppressive pathway
and increases the sensitivity of cervical cancer cells to chemotoxic drugs.
HMGA1 decrease further impairs E6/E7 enhanceosome and contrib-
utes to the negative control of the expression of the HPV oncogenes.
In conclusion, we showed that the increased HMGA1 expression
in cervical carcinoma is directly sustained by HPV infection and is
relevant for cervical carcinogenesis.
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